High-dose-rate brachytherapy with local injection of bleomycin for N0 oral tongue cancer - The possibilities of the control of tumor implant by inserting applicators and the decrease in tumor dose

Ohga Saiji, Uehara Satoru, Miyoshi Makoto, Jingu Kenichi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Twenty eight patients with N0 oral tongue cancer were treated with high-dose-rate (HDR) interstitial brachytherapy combined with local injection of bleomycin between December 1997 and June 2001 at the Department of Radiology, National Kyushu Medical Center Hospital. A median dose of 5 mg of Bleomycin was injected locally and 16-20 Gy were delivered to the surroundings of applicators for the control of the tumor implant for initial two days. Two-year local recurrence-free survival rate was 96 % (T1, 2: 100 % (8/8, 15/ 15), T3: 80 % (4/5)). Two-year secondary neck node metastasis rate was 7.1 % (T1: 12.5 % (1/8), T2: 6.7 % (1/15), T3: 0 % (0/5)). There were no tumor implant in any patients. We tried to decrease the minimal tumor dose step by step. The group with a median minimal tumor dose of 60 Gy, 50 Gy, and 40 Gy had a local recurrence rate of 12.5 % (1/8), 0 % (0/14), 0 % (0/6), respectively. Local recurrent rates were not increase by decreasing a minimal tumor dose. Two patients (7%) had secondary neck node metastasis. Late adverse effects were tongue ulcer: 11 % (3/28), oral floor ulcer: 4 % (1/28), and osteonecrosis: 4 % (1/28). These results suggest that control of the tumor implant and the decrease in minimal tumor dose below 60 Gy may be possible with the local injection of bleomycin and delivering doses to the area surroundings the applicators when N0 tongue cancer is treated using 192Ir-HDR brachytherapy.

Original languageEnglish
Pages (from-to)47-50
Number of pages4
JournalNippon Acta Radiologica
Volume63
Issue number1
Publication statusPublished - Jan 25 2003
Externally publishedYes

Fingerprint

Tongue Neoplasms
Mouth Neoplasms
Bleomycin
Brachytherapy
Injections
Neoplasms
Neck
Oral Ulcer
Neoplasm Metastasis
Mouth Floor
Recurrence
Osteonecrosis
Tongue
Radiology
Ulcer
Survival Rate

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging
  • Oncology

Cite this

High-dose-rate brachytherapy with local injection of bleomycin for N0 oral tongue cancer - The possibilities of the control of tumor implant by inserting applicators and the decrease in tumor dose. / Saiji, Ohga; Satoru, Uehara; Makoto, Miyoshi; Kenichi, Jingu.

In: Nippon Acta Radiologica, Vol. 63, No. 1, 25.01.2003, p. 47-50.

Research output: Contribution to journalArticle

@article{dbe11d713a47465d8e0c7304069eb61c,
title = "High-dose-rate brachytherapy with local injection of bleomycin for N0 oral tongue cancer - The possibilities of the control of tumor implant by inserting applicators and the decrease in tumor dose",
abstract = "Twenty eight patients with N0 oral tongue cancer were treated with high-dose-rate (HDR) interstitial brachytherapy combined with local injection of bleomycin between December 1997 and June 2001 at the Department of Radiology, National Kyushu Medical Center Hospital. A median dose of 5 mg of Bleomycin was injected locally and 16-20 Gy were delivered to the surroundings of applicators for the control of the tumor implant for initial two days. Two-year local recurrence-free survival rate was 96 {\%} (T1, 2: 100 {\%} (8/8, 15/ 15), T3: 80 {\%} (4/5)). Two-year secondary neck node metastasis rate was 7.1 {\%} (T1: 12.5 {\%} (1/8), T2: 6.7 {\%} (1/15), T3: 0 {\%} (0/5)). There were no tumor implant in any patients. We tried to decrease the minimal tumor dose step by step. The group with a median minimal tumor dose of 60 Gy, 50 Gy, and 40 Gy had a local recurrence rate of 12.5 {\%} (1/8), 0 {\%} (0/14), 0 {\%} (0/6), respectively. Local recurrent rates were not increase by decreasing a minimal tumor dose. Two patients (7{\%}) had secondary neck node metastasis. Late adverse effects were tongue ulcer: 11 {\%} (3/28), oral floor ulcer: 4 {\%} (1/28), and osteonecrosis: 4 {\%} (1/28). These results suggest that control of the tumor implant and the decrease in minimal tumor dose below 60 Gy may be possible with the local injection of bleomycin and delivering doses to the area surroundings the applicators when N0 tongue cancer is treated using 192Ir-HDR brachytherapy.",
author = "Ohga Saiji and Uehara Satoru and Miyoshi Makoto and Jingu Kenichi",
year = "2003",
month = "1",
day = "25",
language = "English",
volume = "63",
pages = "47--50",
journal = "Nippon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica",
issn = "0048-0428",
publisher = "Japan Radiological Society",
number = "1",

}

TY - JOUR

T1 - High-dose-rate brachytherapy with local injection of bleomycin for N0 oral tongue cancer - The possibilities of the control of tumor implant by inserting applicators and the decrease in tumor dose

AU - Saiji, Ohga

AU - Satoru, Uehara

AU - Makoto, Miyoshi

AU - Kenichi, Jingu

PY - 2003/1/25

Y1 - 2003/1/25

N2 - Twenty eight patients with N0 oral tongue cancer were treated with high-dose-rate (HDR) interstitial brachytherapy combined with local injection of bleomycin between December 1997 and June 2001 at the Department of Radiology, National Kyushu Medical Center Hospital. A median dose of 5 mg of Bleomycin was injected locally and 16-20 Gy were delivered to the surroundings of applicators for the control of the tumor implant for initial two days. Two-year local recurrence-free survival rate was 96 % (T1, 2: 100 % (8/8, 15/ 15), T3: 80 % (4/5)). Two-year secondary neck node metastasis rate was 7.1 % (T1: 12.5 % (1/8), T2: 6.7 % (1/15), T3: 0 % (0/5)). There were no tumor implant in any patients. We tried to decrease the minimal tumor dose step by step. The group with a median minimal tumor dose of 60 Gy, 50 Gy, and 40 Gy had a local recurrence rate of 12.5 % (1/8), 0 % (0/14), 0 % (0/6), respectively. Local recurrent rates were not increase by decreasing a minimal tumor dose. Two patients (7%) had secondary neck node metastasis. Late adverse effects were tongue ulcer: 11 % (3/28), oral floor ulcer: 4 % (1/28), and osteonecrosis: 4 % (1/28). These results suggest that control of the tumor implant and the decrease in minimal tumor dose below 60 Gy may be possible with the local injection of bleomycin and delivering doses to the area surroundings the applicators when N0 tongue cancer is treated using 192Ir-HDR brachytherapy.

AB - Twenty eight patients with N0 oral tongue cancer were treated with high-dose-rate (HDR) interstitial brachytherapy combined with local injection of bleomycin between December 1997 and June 2001 at the Department of Radiology, National Kyushu Medical Center Hospital. A median dose of 5 mg of Bleomycin was injected locally and 16-20 Gy were delivered to the surroundings of applicators for the control of the tumor implant for initial two days. Two-year local recurrence-free survival rate was 96 % (T1, 2: 100 % (8/8, 15/ 15), T3: 80 % (4/5)). Two-year secondary neck node metastasis rate was 7.1 % (T1: 12.5 % (1/8), T2: 6.7 % (1/15), T3: 0 % (0/5)). There were no tumor implant in any patients. We tried to decrease the minimal tumor dose step by step. The group with a median minimal tumor dose of 60 Gy, 50 Gy, and 40 Gy had a local recurrence rate of 12.5 % (1/8), 0 % (0/14), 0 % (0/6), respectively. Local recurrent rates were not increase by decreasing a minimal tumor dose. Two patients (7%) had secondary neck node metastasis. Late adverse effects were tongue ulcer: 11 % (3/28), oral floor ulcer: 4 % (1/28), and osteonecrosis: 4 % (1/28). These results suggest that control of the tumor implant and the decrease in minimal tumor dose below 60 Gy may be possible with the local injection of bleomycin and delivering doses to the area surroundings the applicators when N0 tongue cancer is treated using 192Ir-HDR brachytherapy.

UR - http://www.scopus.com/inward/record.url?scp=25444531722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25444531722&partnerID=8YFLogxK

M3 - Article

C2 - 12645123

AN - SCOPUS:25444531722

VL - 63

SP - 47

EP - 50

JO - Nippon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica

JF - Nippon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica

SN - 0048-0428

IS - 1

ER -